ERBB2 and breast carcinoma: Dalpiciclib (SHR6390) is a new, orally administered, selective CDK4/6 inhibitor, which has been approved by the National Medical Products Administration for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer [14, 15].